子痫前期筛查与预防实施(IMPRESS)研究
本研究在加拿大公立资助的早孕期联合筛查项目中前瞻性实施基于胎儿医学基金会算法的子痫前期筛查与低剂量阿司匹林预防,1124例患者接受筛查(接受率98.3%),92例(8.2%)筛查阳性,其中62例(86.1%)启动阿司匹林,筛查检出7例早产子痫前期中的5例(71.4%),证实了该项目在加拿大公立医疗环境下的操作可行性。
要点
- 早孕期子痫前期筛查可与唐氏筛查同步进行,平均仅延长约6分钟。
- 高风险(风险评分≥1/100)者推荐阿司匹林162 mg每日一次睡前服用,<16-36周。
- 92例高风险中72例(78.3%)在孕16周前成功联系,62例(86.1%)启动阿司匹林。
核心结论
- 本研究证实了在加拿大公立资助环境下实施基于证据的子痫前期筛查与预防项目的操作可行性,有助于将该服务纳入临床并在地域和省级层面推广。
研究设计与样本
- 前瞻性实施研究,连续纳入2020年12月1日至2021年4月23日转诊接受早孕期联合筛查(11-13+6周)的孕妇,同时提供基于胎儿医学基金会算法的子痫前期筛查,共1124例同意筛查(接受率98.3%)。
主要发现
- 92例(8.2%)筛查阳性;早孕期联合筛查加子痫前期筛查的平均预约时间比单纯早孕期联合筛查延长6分钟,加做子宫动脉多普勒搏动指数平均延长2分钟。
- 92例高风险中72例(78.3%)在孕16周前成功联系,其中62例(86.1%)启动阿司匹林,10例(13.9%)未启动。
- 绩效审计发现平均动脉压测量存在一致性负偏倚(中位数中位数的倍数在10%中<1),其他变量满意。
- 发生7例早产子痫前期(0.69%),高风险组5例、低风险组2例;筛查检出7例中的5例(71.4%),校正阿司匹林治疗效果后性能改善。
关键数值与推荐
- 基于胎儿医学基金会算法计算早产子痫前期(<37周)风险,风险评分≥1/100者推荐使用阿司匹林162 mg每日一次睡前服用,<16-36周。
临床怎么用
- 可在公立资助的早孕期联合筛查项目中同步实施子痫前期筛查,并需关注平均动脉压测量的质量控制。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preeclampsia affects between 2% and 5% of pregnancies and is one of the leading causes of perinatal morbidity and mortality worldwide. Despite strong evidence that the combination of systematic preeclampsia screening based on the Fetal Medicine Foundation preeclampsia risk calculation algorithm with treatment of high-risk patients with low-dose aspirin reduces the incidence of preterm preeclampsia more than currently used risk-factor-based screening, real-world implementation studies have not yet been done in Canada. OBJECTIVE: This study aimed to assess the operational feasibility of implementing first-trimester screening and prevention of preterm preeclampsia (<37 weeks) alongside a publicly funded first-trimester combined screening program for aneuploidies. STUDY DESIGN: This was a prospective implementation study. Consecutive pregnant patients referred for first-trimester combined screening (11-13+6 weeks) were offered screening for preeclampsia based on the Fetal Medicine Foundation algorithm concomitantly with their aneuploidy screen. Consenting participants were screened using maternal risk factors, mean arterial pressure, uterine artery Doppler pulsatility index, pregnancy-associated plasma protein-A, and placental growth factor. Risk for preterm preeclampsia (<37 weeks) was calculated using the Fetal Medicine Foundation algorithm, and individuals with a risk score ≥1 per 100 were recommended to use aspirin (162 mg once daily at bedtime, <16-36 weeks). Implementation metrics assessed included: acceptability, operational impact, proportion of aspirin initiation, quality and safety measures, and screen performance. RESULTS: Between December 1, 2020 and April 23, 2021, 1124 patients consented to preeclampsia screening (98.3% uptake), and 92 (8.2%) screened positive. Appointments for patients receiving first-trimester combined screening aneuploidy and preeclampsia screening averaged 6 minutes longer than first-trimester combined screening alone, and adding uterine artery Doppler pulsatility index averaged 2 minutes. Of the 92 patients who screened as high-risk for preeclampsia, 72 (78.3%) were successfully contacted before 16 weeks' gestation. Of these, 62 (86.1%) initiated aspirin, and 10 (13.9%) did not. Performance audit identified a consistent negative bias with mean arterial pressure measurements (median multiple of the median <1 in 10%); other variables were satisfactory. There were 7 cases of preterm preeclampsia (0.69%): 5 and 2 in the high- and low-risk groups, respectively. Screening detected 5 of 7 (71.4 %) preterm preeclampsia cases, with improved performance after adjustment for aspirin treatment effect. CONCLUSION: This study confirms the operational feasibility of implementing an evidence-based preeclampsia screening and prevention program in a publicly funded Canadian setting. This will facilitate implementation into clinical service and the scaling up of this program at a regional and provincial level.
引用
- Johnson JM, Walsh JD, Okun NB, et al. The Implementation of Preeclampsia Screening and Prevention (IMPRESS) Study. Am J Obstet Gynecol MFM. 2022. PMID: 36400421. doi:10.1016/j.ajogmf.2022.100815
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。